Compare AbbVie Inc (ABBV) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? AbbVie Inc trades at $247.56 (market cap $441.94B), while ProShares UltraPro Short QQQ ETF trades at $37.11. The key difference: AbbVie Inc pays a 2.77% dividend while ProShares UltraPro Short QQQ ETF pays none, and AbbVie Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | SQQQ | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $263.58 | $92.95 |
52-Week Low | $197.38 | $36.31 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
SQQQ, a 3x leveraged inverse ETF tracking the Nasdaq-100, trades at $37.15, down 1.56% on the day. Technical indicators are bearish overall, with moving averages signaling selling pressure, though oscillators are neutral. The ETF is designed for short-term tactical use, not long-term holding, due to daily resets that erode value over time.
The outlook for SQQQ is highly speculative, offering potential gains if the Nasdaq-100 declines, but risks are severe, including rapid decay from leverage and volatility decay. It may serve as a hedge for QQQ holdings but is unsuitable as a standalone investment given its long-term performance history of significant losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
